Tumor-induced osteomalacia and the regulation of phosphate homeostasis

Bone

Volumn 27, Issue 3, 2000, Pages 333-338

  Kumar, R ^a  

^a MAYO CLINIC   (United States)

Author keywords

'Phosphatonin'; 1,25 dihydroxyvitamin D; Osteomalacia; PHEX; Phosphate; Rickets

Indexed keywords

CALCITRIOL; CYCLIC AMP; MUTANT ENDOPEPTIDASE; MUTANT PROTEIN; PHOSPHATE; PHOSPHATONIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; CLINICAL FEATURE; CYCLIC AMP BLOOD LEVEL; ENZYME ACTIVITY; HUMAN; METABOLIC REGULATION; OSTEOMALACIA; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PROTEIN ANALYSIS; REVIEW; TUMOR; VITAMIN D RESISTANT RICKETS;

EID: 0033847087     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00334-3     Document Type: Editorial

References (72)

1. Aschinberg L.C., Solomon L.M., Zies P.M., Justice P., Rosenthal I.M. Vitamin D-resistant rickets associated with epidermal nevus syndrome demonstration of a phosphaturic substance in the dermal lesions . J Pediatr. 91:1977;56-60.
2. Aurbach G.D., Heath D.A. Parathyroid hormone and calcitonin regulation of renal function. Kidney Int. 6:1974;331-345.
3. Austin L.A., Heath H.I. Calcitonin physiology and pathophysiology . N Engl J Med. 304:1981;269-278.
4. Beck L., Karaplis A.C., Amizuka N., Hewson A.S., Ozawa H., Tenenhouse H.S. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA. 95:1998;5372-5377.
5. Beck L., Soumounou Y., Martel J., Krishnamurthy G., Gauthier C., Goodyer C.G., Tenenhouse H.S. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest. 99:1997;1200-1209.
6. Berndt T.J., Knox F.G. Renal regulation of phosphate excretion. Seldin D.W., Giebisch G. The Kidney Physiology and Pathophysiology . 1992;2511-2532 Raven Press, New York.
7. Berndt T.J., Knox F.G. Renal handling of phosphate. Massry S.G., Glassock R.J. Massry & Glassock's Textbook of Nephrology. 1995;388-398 Williams & Wilkins, Baltimore, MD.
8. Bonjour, J.-P., Preston, C., Rizzoli, R., and Fleisch, H. Vitamin D metabolites and phosphate transport. In Copp, D. H. and Talmage, R. V., Ed. Endocrinology of Calcium Metabolism. Amsterdam: Excerpta Medica; 1978; 421:172-177.
9. Brandis M., Harmeyer J., Kaune R., Mohrmann M., Murer H., Zimolo Z. Phosphate transport in brush border membranes from control and rachitic pig kidney and small intestine. J Physiol. 384:1987;479-490.
10. Cai Q., Hodgson S.F., Kao P.C., Lennon V.A., Klee G.G., Zinsmiester A.R., Kumar R. Inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 330:1994;1645-1649.
11. Chang A.C., Dunham M.A., Jeffrey K.J., Reddel R.R. Molecular cloning and characterization of mouse stanniocalcin cDNA. Mol Cell Endocrinol. 124:1996;185-187.
12. Chang A.C., Janosi J., Hulsbeek M., de Jong D., Jeffrey K.J., Noble J.R., Reddel R.R. A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol. 112:1995;241-247.
13. Chang A.C., Reddel R.R. Identification of a second stanniocalcin cDNA in mouse and human stanniocalcin 2 . Mol Cell Endocrinol. 141:1998;95-99.
14. Chase L.R., Aurbach G.D. Parathyroid function and the renal excretion of 3′5′-adenylic acid. Proc Natl Acad Sci USA. 58:1967;518-525.
15. Chase L.R., Aurbach G.D. Renal adenyl cyclase anatomically separate sites for parathyroid hormone and vasopressin . Science. 159:1968;545-547.
16. Chen T.C., Castillo L., Korycka-Dahl M., DeLuca H.F. Role of vitamin D metabolites in phosphate transport of rat intestine. J Nutr. 104:1974;1056-1060.
17. De Niu P., Olsen H.S., Gentz R., Wagner G.F. Immunolocalization of stanniocalcin in human kidney. Mol Cell Endocrinol. 137:1998;155-159.
18. Drezner M.K. Disorders of vitamin D metabolism rickets and osteomalacia . Manolagas S.C., Olefsky J.M. Metabolic Bone and Mineral Disorders. 1988;103-129 Churchill Livingstone, New York.
19. Drezner M.K. Tumor-induced osteomalacia. Favus M.J. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 1999;331-336 Lippincott Williams & Wilkins, Philadelphia, PA.
20. Drezner M.K. PHEX gene and hypophosphatemia. Kidney Int. 57:2000;9-18.
21. Ellis T.J., Wagner G.F. Post-transcriptional regulation of the stanniocalcin gene by calcium. J Biol Chem. 270:1995;1960-1965.
22. Fleisch H., Bonjour J.-P., Rizzoli R., Hugi K. Effect of vitamin D metabolites on calcium and phosphate metabolism. Contr Nephrol. 13:1978;96-103.
23. Francis F., Hennig S., Korn B., Reinhardt R., de Jong P., Poustka A., Lehrach H., Rowe P.S.N., Goulding J.N., Summerfield T., Mountford R., Read A.P., Popowska E., Pronicka E., Davies K.E., O'Riordan J.L.H., Econs M.J., Nesbitt T., Drezner M.K., Oudet C., Hanauer A., Strom T., Mendl A., Lorenz B., Cagnoli M., Mohnike K.L., Murken J., Mettinger T. Positional cloning of PEX a phosphate regulating gene with homologies to endopeptidases is detected in patients with X-linked hypophosphatemic rickets . Nat Genet. 11:1995;130-136.
24. Fraser R.A., Kaneko T., Pang P.K., Harvey S. Hypo- and hypercalcemic peptides in fish pituitary glands. Am J Physiol. 260:1991;R622-R666.
25. Fukumoto Y., Tarui S., Tsukiyama K., Ichihara K., Moriwaki K., Nonaka K., Mizushima T., Kobayashi Y., Dokoh S., Fukunaga M., Morita R. Tumor-induced vitamin D-resistant hypophosphatemic osteomalacia associated with proximal renal tubular dysfunction and 1,25-dihydroxyvitamin D deficiency. J Clin Endocrinol Metabol. 49:1979;873-878.
26. 3 on renal phosphate transport. Endocrine Res Commun. 9:1982;135-143.
27. Harrison H.E. Oncogenous rickets possible elaboration by a tumor of a humoral substance inhibiting tubular reabsorption of phosphate . Pediatrics. 52:1973;432-434.
28. Hilfiker H., Hattenhauer O., Traebert M., Forster I., Murer H., Biber J. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci USA. 95:1998;14564-14569.
29. Ishibashi K., Miyamoto K., Taketani Y., Morita K., Takeda E., Sasaki S., Imai M. Molecular cloning of a second human stanniocalcin homologue (STC2). Biochem Biophys Res Commun. 250:1998;252-258.
30. 3 -stimulated active uptake of phosphate by rat jejunum. Am J Physiol. 243:1982;E470-E475.
31. Kumar R. Phosphatonin - a new phosphaturetic hormone - (lessons from tumor-induced osteomalacia and x-linked hypophosphatemia). Nephrol Dial Transplant. 12:1997;11-13.
32. Kumar R. New concepts concerning the regulation of renal phosphate excretion. News Physiol Sci. 12:1997;211-214.
33. Kumar R., Haugen J.D., Wieben E.D., Londowski J.M., Cai Q. Inhibitors of renal epithelial phosphate transport in tumor-induced osteomalacia and uremia. Proc Assoc Am Physicians. 107:1995;296-305.
34. Lajeunesse D., Meyer R.A. Jr, Hamel L. Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse. Kidney Int. 50:1996;1531-1538.
35. Lipman M.L., Panda D., Bennett H.P.J., Henderson J.E., Shane E., Shen Y., Goltzman D., Karaplis A.C. Cloning of human PEX cDNA expression, subcellular localization and endopeptidase activity . J Biol Chem. 273:1998;13729-13737.
36. Lobaugh B., Burch W.M. Jr, Drezner M.K. Abnormalities of vitamin D metabolism and action in the vitamin D resistant rachitic and osteomalacic diseases. Kumar R. Vitamin D Basic and Clinical Aspects . 1984;655-720 Martinus Nijhoff, Boston, MA.
37. Lu M., Wagner G.F., Renfro J.L. Stanniocalcin stimulates phosphate reabsorption by flounder renal proximal tubule in primary culture. Am J Physiol. 267:1994;R1356-R1362.
38. Marx S.J., Woodward C.J., Aurbach G.D. Calcitonin receptors of kidney and bone. Science. 178:1972;999-1001.
39. Meyer R.A. Jr, Meyer M.H., Gray R.W. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res. 4:1989;493-500.
40. Meyer R.A. Jr, Tenenhouse H.S., Meyer M.H., Klugerman A.H. The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphatemic mice persists after parathyroidectomy. J Bone Miner Res. 4:1989;523-532.
41. Moore E.E., Kuestner R.E., Conklin D.C., Whitmore T.E., Downey W., Buddle M.M., Adams R.L., Bella L.A., Thompson D.L., Wolf A., Chen L., Stamm M.R., Grant F.J., Lok S., Ren H., De Jongh K.S. Stanniocalcin 2 characterization of the protein and its localization to human pancreatic α cells . Horm Metab Res. 31:1999;406-414.
42. Morita K., Miyamoto K., Ishibashi K., Imai M., Miyauchi A., Taketani Y., Yamamoto H., Takeda E. Molecular cloning and functional analysis of a second human stanniocalcin homologue (STC2). J Bone Miner Res. 14:(Suppl):1999;210.
43. Murer H., Forster I., Hernando N., Lambert G., Traebert M., Biber J. Posttranscriptional regulation of the proximal tubule NaPi-II transporter in response to PTH and dietary P(i). Am J Physiol. 277:1999;F676-F684.
44. Nelson A.E., Mason R.S., Hogan J.J., Diamond T., Robinson B.G. Tumor expression studies indicate that HEM-1 is unlikely to be the active factor in oncogenic osteomalacia. Bone. 23:1998;549-553.
45. Nelson A.E., Namkung H.J., Patava J., Wilkinson M.R., Chang A.C., Reddel R.R., Robinson B.G., Mason R.S. Characteristics of tumor cell bioactivity in oncogenic osteomalacia. Mol Cell Endocrinol. 124:1996;17-23.
46. Nesbitt T., Coffman T.M., Griffiths R., Drezner M.K. Crosstransplantation of kidneys in normal and hyp-mice evidence that the hyp-mouse phenotype is unrelated to an intrinsic renal defect . J Clin Invest. 89:1992;1453-1459.
47. Nesbitt T., Fujiwara I., Thomas R., Xiao Z.S., Quarles L.D., Drezner M.K. Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia . J Bone Miner Res. 14:1999;2027-2035.
48. Olsen H.S., Cepeda M.A., Zhang Q.Q., Rosen C.A., Vozzolo B.L. Human stanniocalcin a possible hormonal regulator of mineral metabolism . Proc Natl Acad Sci USA. 93:1996;1792-1796.
49. Park Y.K., Unni K.K., Beabout J.W., Hodgson S.F. Oncogenic osteomalacia a clinicopathologic study of 17 bone lesions . J Korean Med Sci. 9:1994;289-298.
50. Popovtzer M.M. Tumor-induced hypophosphatemic osteomalacia (TUO) evidence for a phosphaturic cyclic AMP-independent action of tumor extract . Clin Res. 29:1981;418A.
51. Popovtzer M.M., Knochel J.P., Kumar R. Disorders of calcium, phosphorus, vitamin D, and parathyroid hormone activity. Schrier R.W. Renal and Electrolyte Disorders. 1997;241-319 Lippincott-Raven, Philadelphia, PA.
52. Puschett J.B. Renal tubular effects of vitamin D and its metabolites. Adv Exp Med Biol. 81:1977;29-40.
53. Puschett J.B., Fernandez P.C., Boyle I.T., Gray R.W., Omdahl J.L., DeLuca H.F. The acute renal tubular effects of 1,25-dihydroxycholecalciferol. Proc Soc Exp Biol Med. 141:1972;379-384.
54. 3 interactions with vasopressin and parathyroid hormone in the vitamin D-depleted rat . J Lab Clin Med. 92:1978;895-903.
55. Reyes-Mugica M., Arnsmeier S.L., Backeljauw P.F., Persing J., Ellis B., Carpenter T.O. Phosphaturic mesenchymal tumor-induced rickets. Pediatr Dev Pathol. 3:2000;61-69.
56. Rowe P.S.N. Cloning of two genes involved in the pathophysiology of tumor osteomalacia (OHO). Bone. 23:(Suppl):1998;653.
57. Rowe P.S., Ong A.C., Cockerill F.J., Goulding J.N., Hewison M. Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia. Bone. 18:1996;159-169.
58. Ryan E.A., Reiss E. Oncogenous osteomalacia review of the world literature of 42 cases and report of two new cases . Am J Med. 77:1984;501-512.
59. Steele T.H., DeLuca H.F. Influence of dietary phosphorus on renal phosphate reabsorption in the parathyroidectomized rat. J Clin Invest. 57:1976;867-874.
60. 3 . Am J Physiol. 229:1975;489-495.
61. Stone M.D., Quincey C., Hosking D.J. A neuroendocrine cause of oncogenic osteomalacia. J Pathol. 167:1992;181-185.
62. Tanaka Y., DeLuca H.F. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys. 154:1973;566-574.
63. 3 in maintaining serum phosphorus and curing rickets. Proc Natl Acad Sci USA. 71:1974;1040-1044.
64. Varghese R., Wong C.K., Deol H., Wagner G.F., DiMattia G.E. Comparative analysis of mammalian stanniocalcin genes. Endocrinology. 139:1998;4714-4725.
65. Wagner G.F., Guiraudon C.C., Milliken C., Copp D.H. Immunological and biological evidence for a stanniocalcin-like hormone in human kidney. Proc Natl Acad Sci USA. 92:1995;1871-1875.
66. Wagner G.F., Jaworski E.M., Haddad M. Stanniocalcin in the seawater salmon structure, function and regulation . Am J Physiol. 274:1998;R1177-R1185.
67. 2+ uptake in young rainbow trout. J Endocrinol. 155:1997;459-465.
68. Wagner G.F., Vozzolo B.L., Jaworski E., Haddad M., Kline R.L., Olsen H.S., Rosen C.A., Davidson M.B., Renfro J.L. Human stanniocalcin inhibits renal phosphate excretion in the rat. J Bone Miner Res. 12:1997;165-171.
69. Weidner N., Bar R.S., Weiss D., Strottmann M.P. Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer. 55:1985;1691-1705.
70. Wilkins G.E., Granleese S., Hegele R.G., Holden J., Anderson D.W., Bondy G.P. Oncogenic osteomalacia evidence for a humoral phosphaturic factor . J Clin Endocrinol Metab. 80:1995;1628-1634.
71. World International Property Organization, Rowe, P. (Inventor/Applicant). A over polypeptide hormone phosphatonin. Publication number WO99/60017, 25 November 1999.
72. Yoshiko Y., Son A., Maeda S., Igarashi A., Takano S., Hu J., Maeda N. Evidence for stanniocalcin gene expression in mammalian bone. Endocrinology. 140:1999;1869-1874.